Journals Library

An error occurred retrieving content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Martin Underwood 1,2,*, Felix Achana 1, Dawn Carnes 3, Sandra Eldridge 3, David R Ellard 1,2, Frances Griffiths 4, Kirstie Haywood 4, Siew Wan Hee 4, Helen Higgins 1, Dipesh Mistry 1, Hema Mistry 1,2, Sian Newton 3, Vivien Nichols 1, Chloe Norman 1, Emma Padfield 1, Shilpa Patel 1, Stavros Petrou 1,5, Tamar Pincus 6, Rachel Potter 1, Harbinder Sandhu 1, Kimberley Stewart 1, Stephanie JC Taylor 3, Manjit Matharu 7

1 Warwick Clinical Trials Unit, Division of Health Sciences, University of Warwick, Coventry, UK
2 University Hospitals Coventry and Warwickshire, Coventry, UK
3 Centre for Primary Care and Public Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
4 Division of Heath Sciences, Warwick Medical School, University of Warwick, Coventry, UK
5 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
6 Department of Psychology, Royal Holloway University of London, London, UK
7 Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
* Corresponding author Email: m.underwood@warwick.ac.uk

Disclosure of interests of authors

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/PLJL1440.

Primary conflicts of interest: Martin Underwood reports personal fees from the National Institute for Health and Care Research (NIHR) and grants as chief investigator or co-investigator from NIHR (NIHR202614, 027/0089, 14/25/05, NIHR132803, 17/60/22, 12/196/08, NIHR12876, 16/77/02, NIHR131316, 16/167/56, NIHR131407, NIHR132046, NIHR132871, NIHR134398, 16/61/18, NIHR131629, 15/15/09, 13/146/02, 17/129/02 and 14/224/04), the Australian National Health and Medical Research Council (APP1164268), the Norwegian Medical research council (326732/ABHO), Versus Arthritis (Chesterfield, UK), Stryker Ltd (Portage, MI, USA) and Serco Group plc (Hook, UK). He also reports expenses for attending multiple professional conferences, personal fees from Consortium for Advanced Research Training in Africa (Nairobi, Kenya), outside the permitted work. Plus personal fees from Clinvivo Ltd (Tenterden, UK), for which he is also a director and shareholder. Frances Griffiths reports grants from NIHR during the conduct of the study (ISRCTN17941313, ISRCTN14161293, ISRCTN10093277, ISRCTN14933421 and ISRCTN12698674). Stephanie Taylor reports grants from NIHR during the conduct of the study [14/244/04, RP-PG-0707-10189, NIHR202037, NIHR129937, RP-DG-1213-10010, RP-PG-1016-20008, RP-PG-0616-20002, RP-PG-0216-20001 NIHR130999, NIHR Health Technology Assessment (HTA) 14/224/04, NIHR HTA 13/146/2 and NIHR HTA 17/129/02]. Manjit Matharu reports grants, personal fees and honorarium for serving on the advisory board of Allergan plc (Dublin, Ireland), honorarium for serving on the advisory board of Novartis Pharmaceuticals UK Ltd (London, UK), personal fees and honorarium for serving on the advisory board of Eli Lilly and Company (Indianapolis, IN, USA), personal fees and honorarium for serving on the advisory board of Teva Pharmaceuticals Industries Ltd (Tel Aviv-Yafo, Israel), grants from Abbott Laboratories (Abbott Park, IL, USA), grants from Medtronic plc (Dublin, Ireland), grants from electroCore (Rockaway, NJ, USA) and personal fees and honorarium for serving on the advisory board of Salvia BioElectronics (Eindhoven, the Netherlands). In addition, Manjit Matharu has a patent WO2018051103A1 issued. Harbinder Sandhu is a chief investigator and co-investigator on research projects funded by NIHR (NIHR202670, NIHR132046, NIHR HTA 17/129/02, PG/19/22/34203 and NIHR HTA 14/224/04). Harbinder Sandhu is also the director of a limited company providing pain management and other psychological services. Shilpa Patel is a co-investigator on a research project funded by NIHR (NIHR202614). Shilpa Patel is also the director of a limited company providing pain management and other psychological services.

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

 

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions